RxDoctor Payments Data

Shabbir Motiwala, MD

Family Medicine · Columbus, GANPI 1306820253

Payments from drug & device makers

$1,629in general payments, 2019–2025

Across 75 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$324
  • Boehringer Ingelheim$201
  • Abbott$192
  • Novo Nordisk$169
  • AbbVie$155
  • AstraZeneca$136
  • plus $452 from 12 others

What the payments were for

  • Food & beverage$1,61799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,629 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$27,215
Medicare patients
71
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate14$18,650
OzempicSemaglutide11$10,135
InvokanaCanagliflozin11$6,408
LivaloPitavastatin Calcium11$6,170
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,687
Amlodipine-AtorvastatinAmlodipine/Atorvastatin24$2,213
Humulin RInsulin Regular, Human12$1,725
Atorvastatin Calcium223$1,573
Lansoprazole12$775
Pravastatin Sodium59$759
Gabapentin32$633
Amlodipine Besylate143$563
Clonidine Hcl34$539
Nifedipine ErNifedipine13$426
Omeprazole37$408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$98$18,65014 claims
Novo NordiskOzempic$169$10,13511 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$6,17011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →